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Abstract
The focus of this research is on cell migration and how it can be better understood
through the use of small molecules that modulate cell migratory activity. The results have
particular relevance in the realm of cancer pharmacology. Cardiac glycosides, which are known
inhibitors of the eukaryotic Na+/K+-ATPase, have been determined to have antimigratory
activities through the screening of several small molecule libraries. Here we investigate the
antimigratory activities of the cardiac glycoside digitoxin as well as its analogs that we
synthesized. Antimigratory activity was determined by conducting a wound closure assay with
MDA-MB-231 human breast carcinoma cells. This antimigratory activity was compared to the
inhibitory activity when Na+/K+-ATPase was treated with digitoxin and its analogs in a Na+/K+ATPase assay. A coloration between wound closure activity Na+/K+-ATPase inhibitory activity
provides evidence that cardiac glycosides inhibit cell migration through their interaction with the
Na+/K+-ATPase protein. This research will provide the grounds to study the specific pathways in
which Na+/K+-ATPase is linked to the regulation of cell migration.
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Chapter One: Introduction
1A. What are cardiac glycosides?
Cardiac glycosides are a class of naturally occurring small molecules that have been used
as drugs to treat heart conditions, namely congestive heart failure and cardiac arrhythmias such
as atrial fibrillation. Recorded medicinal use of cardiac glycosides dates back as far as 1785,
when Sir William Withering first described using the foxglove plant as a treatment for “dropsy,”
or edema associated with congestive heart failure.1,2 The foxglove plant, Digitalis purpurea, is
still used as a source for extracts containing the cardiac glycoside digoxin, which has well
studied inotropic properties that have been shown to increase myocardial contractility.2
Some of the most well known and well studied cardiac glycosides include digoxin,
digitoxin, ouabain, oleandrin, and bufalin. Although these natural molecules each have their own
unique chemical structure, they all share a conserved core framework.
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As the name cardiac glycoside implies, each molecule has a glycone or sugar portion.
The glycone can be a monosaccharide such as the single L-rhamnose on ouabain or it can be a
polysaccharide chain such as the 2-deoxy trisaccharide of digitoxin. The sugars tend to be the
part of the chemical structure that has the least significant effects on the biological activities of
the molecules.
The glycone portion of the cardiac glycoside can be cleaved by hydrolysis to leave the
aglycone. The suffix –genin is used to indicate that the structure only includes the aglycone. So
the aglycone of digitoxin is called digitoxigenin. The aglycone is composed of two important
regions: the tetracyclic steroidal core, and the lactone on C-17. The steroid moiety consists of 3
six-membered rings and 1 three-membered ring for a total of four fused rings. The way in which
these four rings are fused provides them with a three dimensional structure that is very important
to the overall shape of the entire cardiac glycoside and its biological activity. Rings A and B are
fused in a cis conformation and rings C and D are also fused in a cis conformation. However, the
two center rings B and C are fused in trans conformation that gives the steroid core a slight twist
and a curve into a crescent shape. The level of oxidation of the steroid core with hydroxyl group
varies among the different cardiac glycosides. In fact, the only difference in the structures of
digoxin and digitoxin is the hydroxyl group on the C-12 of digoxin. Additional hydroxyl groups
on the tetracyclic steroidal core can increase the solubility of the molecule.
The lactone ring in cardiac glycosides is always on C-17 and determines which of two
groups the cardiac glycoside falls into. If the lactone ring is a butenolide ring, like in ouabain and
digoxin/digitoxin, then that cardiac glycoside is a cardenolide. If the lactone ring is an α-pyrone
ring, such as in bufalin, then the molecule is classified as a bufadienolide. While cardenolides are
extracted as secondary plant metabolites, bufadienolides are often produced by mammals and
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amphibians as well as plants and are five time as toxic in humans3. Overall, bufadienolides are
the much less common form of cardiac glycosides and due to their higher toxicity, they are not
used in the same pharmacological capacity as cardenolides. With regard to the biological
activities of cardenolides glycosides, the butenolide ring is thought to be more important than the
sugars, but less important than the tetracyclic steroidal core.
The most well studied biological activity of cardiac glycosides is their interaction with
the Na+/K+ ATPase pump, an enzyme found in the plasma membrane of virtually all animal
cells. This enzyme has four subunits; two α subunits that extend into the interior surface of the
cell and two ß subunits that extend into the exterior space around the cell. There are different
isoforms of these subunits that are found in different cells in the body.4 Four different isoforms
of the α subunit (α1, α2, α3, and α4) and three different isoforms of the ß subunit (ß1, ß2, ß3)
have been discovered5 Combinations of these subunits are found throughout different tissues. For
instance, the α1ß1 isoform is present in all cell types, while the α3ß2 heterodimer isoform is less
common, and found in the pineal gland and retinal photoreceptor cells.5 Although it is agreed
upon that cardiac glycosides bind to the α subunits of the Na+/K+ ATPase pump, it is difficult to
say whether cardiac glycosides have stronger affinity to a particular α subunit isoform. Different
studies have shown ouabain to have greater affinity for each α1, α2, and α3 depending on the
study and the type of animal tissue used.
An analysis of a crystal structure of ouabain bound to the Na+/K+ ATPase pump showed
how each of the important structures (the lactone ring, the steroidal core, and the carbohydrate
rhamnose) interact with the transmembrane helices of Na+/K+ ATPase.6 The crystal structure
agrees that the main binding sites for ouabain are the M5 and M6 helices on the α subunit, but it
challenges the previously held idea that ouabain binds to the extracellular surface portion of
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these transmembrane helices.6 Instead, the crystal structure (Figure 1) shows that ouabain is
bound deep within the helices and is held almost entirely within the phospholipid bilayer of the
membrane.6

8

The inotropic properties of cardiac glycosides are a result of inhibition of Na+/K+
ATPase. One of the important physiological functions of this pump is to regulate the ion
concentrations across the cell’s plasma membrane. As the name implies, the Na+/K+ ATPase
pump requires phosphorylation by ATP for each ion exchange to occur. The net result of each
ion exchange is 3 Na+ transported out of the cell, 2 K+ transported into the cell, and one ATP
consumed. When the cardiac glycoside binds to the α subunit of Na+/K+ ATPase in the cardiac
muscle, it stops this Na+/K+ ion exchange and allows for a greater force and velocity of
contraction in the heart.7 In order to understand how this mechanism works, it may be helpful to
briefly describe the normal mechanism of contraction in cardiac muscle.
Muscle contraction starts with the generation of an action potential, or depolarization of
the surface of a cell. This action potential is a result of a rapid exchange of ions across the cell
membrane. Once the action potential is created, there is a release of Ca2+ from the sacroplasmic
reticulum. Ca2+ binds to troponin, the regulatory protein in the interaction between actin and
myosin.8 Actin and myosin will interact and continue to cause muscle contractions until the Ca2+
is no longer present to bind troponin. The cell returns Ca2+ levels back to normal by pumping it
out of the cell in exchange for Na+ flowing down its concentration gradient into the cell.8
When cardiac glycosides bind to Na+/K+ ATPase, they effectively inhibit the exchange of
Na+ and K- ions. This disrupts the concentration gradient of Na+, and prevents Na+ from flowing
down its gradient into the cell in exchange for Ca2+.9 Since there is no way to effectively remove
Ca2+ from the cell, Ca2+continues to binds troponin and allow for the interaction of actin and
myosin. This results in greater force in the contractions of the cardiac muscle.10
Although it is most well known for its ion exchange activity, the Na+/K+ ATPase pump is
becoming increasingly thought of as an isoenzyme.5 Rather than accounting for the activity of
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one biological process, it is a critical enzyme for an entire host of critical cell functions. Na+/K+
ATPase is responsible for creating the electrochemical gradient across the plasma membrane that
allows for the secondary transport of various ions, substrates, and neurotransmitters via Na+coupled transport systems.5 The electrochemical gradient created by Na+/K+ ATPase is also
critical to renal physiology, as it facilitates the reabsorption of water in the proximal convoluted
tubules of the nephrons to allow for the maintenance of homeostasis of electrolytes and fluids in
the body.5 The ability of Na+/K+ ATPase to act as a receptor for a signal transduction pathway is
also a very important part in its role as an isoenzyme.
Considering the many functions of Na+/K+ ATPase, it is not surprising that the interaction
of cardiac glycosides with Na+/K+ ATPase effects several cell processes besides its most well
studied relationship with cardiac muscle contraction. These cell processes include activation of
cytoplasmic Ca2+ oscillation, cell growth, induction of apoptosis, glycogen synthesis, inhibition
of endocytosed membrane traffic, and the production of high density microtubule granules.11
Some of these effects are a result of cardiac glycosides inhibiting the ion pumping of the
ATPase. However, more studies are showing that these functions may the result of Na+/K+
ATPase acting as a receptor for cardiac glycosides and starting a signal cascade triggered by
phosphorylation , and not necessarily correlated with the inhibition of the Na+/K+ ion pumping.11

1B. The Importance of Cell Migration
The ability of cells to migrate is of great physiological significance. Cell migration is
necessary for many normal cell processes, such as embryogenesis, immunoresponses, and wound
closure. In normal cells, the inhibition of cell migration would create significant problems in
growth, development, and maintenance of healthy tissues. However, there are times when the
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blocking of cell migration would be beneficial. Inhibiting cell migration could help to obstruct
diseased states that rely on the movement of cells, including tumor formation, tumor metastasis,
and vascularization.
Cell migration is a very complex process involving the components of the cytoskeleton;
actin, microtubules, and intermediate filaments. Microtubules are the primary facilitators of
ciliary and flagellar movement and they also interact with actin and create cell polarity in regular
cell movement.12 Intermediate filaments are more important for structural support and they do
not play as significant of a role in cell movement other than signal transduction.12 This leaves
actin as the primary driving force in the cytoskeleton that allows for cell migration.
The start of cell migration requires a protrusion of the cell membrane in direction of
movement. This protrusion is caused by a change in the structure of actin network within the
cell. The actin network is dynamic and can change as a result of lengthening actin chains by
polymerization, disassembly of actin filaments into free monomers, crosslinking of actin
filaments, and restructuring of actin density and organizational geometry.12 This dynamic actin
network begins to change once directionality and polarity has been established along the plane of
motion. Then the actin polymerizes to form filaments that create a protrusion of the outer
membrane, called the leading edge, in the direction of migration. Actin polymerization is the
assembly of free actin monomers (G-actin) into a polar polymer (F-actin). The F-actin is
considered polar because it has two different ends, a barbed end and a pointed end. The barbed
end of F-actin is the growing end, because it is easily accessible to rapid polymerization by the
free G-actin with the help of ATP, Mg2+, and a G-actin binding protein.12 After polymerization
of G-actin into F-actin has created a protrusion or leading edge, actin and myosin work together
to create contractions and provide the force to pull the cell body forward, retract the lagging
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portion of the cell, and cause detachment from the substratum.12 Integrins also play a very
important role in attachment and detachment from the substratum. Integrins are surface proteins
that serve as adhesion receptors for the extracellular matrix.13 They are regulated by intracellular
signaling mechanisms and they also receive extracellular signals which they relay as intracellular
signals themselves.13
Figure 2 (reproduced with permission)12 provides a very basic representation of the
process of cell migration of animal cells. Although the process may appear simple in the
diagram, it is actually a very complicated process full of intricate signaling cascades and
regulatory pathways. With so many different molecules and pathways involved, there are many
potential targets for inhibition of cell migration. Inhibitors can target either free or polymerized
actin or even the capping protein that regulates binding to the barbed end of F-actin.12 Inhibitors
of cell migration can also target other known, important structures such as microtubules or
integrins. Then there is the host of upstream signaling molecules that all provide targets for the
inhibition of cell migration.

Fig. 2.
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There are remarkably few known small molecule inhibitors of specific proteins that
regulate cytoskeleton dynamics in cell migration.12 Small molecules mimic the much larger
naturally occurring molecules that regulate cytoskeleton dynamics and act as highly useful tools
for understanding cell migration. All of the mechanisms by which cells migrate and methods by
which migration is regulated are still not fully understood12, yet cell migration is still certainly an
appealing target for drugs.

1C. Significance to Cancer Pharmacology
Small molecules that are able to effectively target specific proteins and inhibit cell
migration would have potential application to cancerous cell invasion, the early stages of
cancerous tumor development, as well as metastasis. Inhibition of cell invasion and metastasis
would be particularly useful for controlling the formation of new tumors after unsuccessful
treatment or surgery. This type of inhibition would also amplify the effectiveness of other anticancer drugs targeting containment of solid tumors by stopping cell growth and division.14
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Chapter Two: Synthesis and characterization of digitoxin analogs
2A. Purchase and characterization of commercial digitoxin
Digitoxin 1 was purchased commercially from Acros Organics (CAS number: 71-63-6)
and was used as the starting structure for the synthesis of the rest of the digitoxin analogs.
Digitoxin was soluble in water, methanol, ethyl acetate, and chloroform. In most of the reactions
with digitoxin, methanol was the solvent used. Ethyl
acetate was used as part of the solvent system during
column chromatography to separate reaction products. Both
deuterated chloroform and deuterated methanol were used
as solvent for NMR spectroscopy.
Characterization of 1 was performed using 1H and
13

C NMR spectroscopy. The observed NMR peak values

1 - Digitoxin

matched those found in the literature.15 When synthesizing analogs of 1, these NMR data were
used for comparison. The emergence of new peaks or the loss of peaks were helpful in
confirming structural changes.

2B. Synthesis and characterization of digitoxigenin
Digitoxigenin 2 is the aglycone of digitoxin, and it was synthesized using two different
procedures. The first method for synthesizing 2 was an established procedure for the
deglycosylation of ouabain, a cardiac glycoside very similar in structure to digitoxin.16 Hong
describes the reaction of ouabain octahydrate with acetone-12 N hydrochloric acid (0.4 mL
HCl/100 mL acetone) at 23°C, with the aglycone forming as a precipitate after 10 days under
reaction conditions.16 As shown by reaction A in scheme 1, we used digitoxin 1 as the starting
14

material under the same these same reaction conditions for the synthesis of the digitoxin
aglycone, digitoxigenin 2. The reaction mixture was then separated by column chromatography
to purify product 2. This procedure that Hong described for the
Scheme 1

A

B
2
1
deglycosylation of ouabain was successful for digitoxin, however the 10 to 14 days required for
the reaction to reach completion was not ideal. So we switched to a different procedure that also
used acid catalyzed hydrolysis, but under different reaction conditions allowing for the synthesis
of 2 in several hours instead of 10 to 14 days.17 The reaction conditions described by Pádua are
shown by reaction B in scheme 1. Under this procedure, 1 was dissolved in methanol and 1M
aqueous HCl. The solution was then refluxed at 55°C for 35 minutes. The reaction products were
then extracted with CHCl3 and neutralized with 3% NaHCO3. Product 2 was purified by column
chromatography.
Characterization was performed by 1H and 13C NMR spectroscopy. The experimental
peak values matched the peak assignments reported by Pádua for both 1H and 13C.
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The synthesis of 2 is important because it results in an analog that is identical to
digitoxin, minus the sugar moiety. Including this analog in the wound closure assay (Chapter
Three) provides valuable information about the way in which cardiac glycosides inhibit cell
migration.
2C. Synthesis and characterization of elimination aglycone side product
Analogs 4a and 4b were at first unintentionally synthesized as side products of the
deglycosylation reaction in an attempt to synthesize 2 under reaction conditions A in scheme 2.

Scheme 2

A
4a
B
4b
1
They appeared as one spot on thin layer chromatography, and they were separated from the
reaction mixture by column chromatography. At the time, I thought that I was likely separating
product 2 from the reaction mixture. However, characterization by 1H and 13C NMR
chromatography revealed that the product I purified was not digitoxigenin. The 13C NMR
showed four downstream peaks that did not match the predicted chemical shifts for 2. These
peaks were in the typical range for alkene carbons at 154.6, 138.5, 129.9, and 116.5 δ (ppm). At
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this point, I did not know the identity of the compound I had isolated, but I had concluded that it
was not 2.
It was not until reading the Pádua et al. study on the biotransformation of digitoxigenin17
that we realized that the substance we isolated from the deglycosylation reaction mixture must be
a mixture of 4a and 4b. This accounted for the downstream 13C signals indicating the presence of
alkenes. Upon comparison of the 1H and the 13C data to the data published by Pádua et al.,17 we
were sure that the reaction product we had isolated from the reaction products was a mixture of
4a and 4b.
Attempts to separate 4a and 4b, by column chromatography were unsuccessful. The Rf
values were identical in every solvent system that was used. They could have been separated by
using a preparative RP-HPLC system,17 but that equipment was not available. For our purposes
we decided that it would be acceptable to use a mixture of 4a and 4b in the wound closure assay
to determine the importance of the steroid core to cell migration inhibitory activity. Additional
4a/4b was synthesized as a side product during the synthesis of 2 under the Pádua reactions
conditions shown in B of Scheme 2.
2D. Synthesis and characterization of 20,22-dihydrodigitoxin
20,22-dihydrodigitoxin 3 was synthesized by reducing the double bond between C20 and
C22 of digitoxin. The starting material, 1, was added to 10% Pd on carbon dissolved in
methanol. The solution in the round bottom flask was sealed with a rubber septum and flushed
first with nitrogen and then with hydrogen gas. The solution was treated with excess hydrogen
gas overnight. The reaction mixture was purified by filtering through celite to remove the
carbon. Thin layer chromatography showed only one compound, with an Rf value very close to
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that of the starting material. Complete conversion of 1 to 3 was assumed, so no further
purification was performed.

Scheme 3

1

3

The product 3 was characterized by 1H and 13C NMR chromatography, which confirmed
complete conversion of 1 to 3. In the 13C NMR of 1, there is a peak with a chemical shift of
117.8 δ (ppm) marking the presence of C22. In the 13C NMR of 3, this peak at 117.8 δ (ppm) is
absent, indicating that the reduction of double bond between C20 and C22 has occurred.
3 is an important analog for providing information about role of the butenolide moiety in
the inhibition of cell migration by cardiac glycosides. The reduction of the double bond changes
the stereochemistry of the lactone ring, which could potentially affect the bond between 3 and its
target protein.

2E. Synthesis and characterization of 20,22-dihydrodigitoxigenin
20,22-dihydrodigitoxigenin was synthesized in two steps under the reaction conditions
shown in Scheme 4. The C20, C22 double bond in 2 proved to be significantly more difficult to
18

reduce than the same bond in 1. Several unsuccessful hydrogenation attempts were made using
the same 10% Pd on carbon as in Scheme 3. Then, we switched to 20% palladium hydroxide on
carbon, and the reaction was successful. The product 5 was characterized by 1H and 13C NMR
chromatography and the reduction of the C20, C22 double bond was confirmed by the absence of
the peak at 117.8 δ (ppm).
Since both the sugar moiety and the butenolide moiety were modified in this synthesis, a
wound closure assay on 5 would not provide as valuable information about the structure-function
relationship between digitoxin and cell migration inhibitory activity. It is better to modify only
one moiety at a time, to see how that specific moiety affects cell migration inhibition. So after an
error occurred during the first wound closure assay of 5, a second assay has not yet been
completed.

Scheme 4

2
1
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5

2F. Attempted synthesis of open butenolide ring analog
The wound closure assay data from 3 gives some information about the butenolide ring
and its effects on cell migration. However, a complete opening of the butenolide ring would
allow for a clearer picture of its importance in the cell migration inhibition process.
The first method we used to try opening the butenolide ring was ozonolysis of digitoxin.
Several unsuccessful ozonolysis attempts were made, using both methanol and methylchloride as
solvents. In several attempts, the spectroscopy showed that the reaction had not gone to
completion and only starting material present. Then in a few attempts, a product was formed, but
the spectroscopy suggested that it was not the product we were looking for.
Ring opening aminolysis was also used to try to open the butenolide ring. We used the
procedure described by Liu for opening lactone rings with benzylamine and sodium 2ethylhexanoate, which acts as a base and a catalyst.18 However this reaction was unsuccessful
when performed on both 1 and 2. In all attempts, there was no addition of the benzylamine,
which would have been visible under UV light and also would have been noticeable in the
spectroscopy.
We would still like to have an analog of digitoxin where the butenolide ring has been
opened. We are hoping that we will be able to reduce the lactone of 3 or 5 to a diol by treating
with DIBAL or lithium aluminum hydride.
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Chapter Three: Inhibition of Cell Migration, Measured by a Wound Closure Assay
3A. Description of cell line
MDA-MB-231 human breast carcinoma cells were obtained from the American Tissue
Culture Collection (ATCC) or Kam C. Yeung of the University of Toledo. This particular cell
line is one of the most commonly used breast cancer cell lines in research labs across the
country. The MDA-MB-231 cell line is well studied, characterized, and cited in the literature.19
It was originally taken from a 51 year-old, Caucasian woman in October of 1973 at the M. D.
Anderson Cancer Center.20 The malignant MDA-MB-231 carcinoma cells were taken from a
pleural effusion that matched the primary tumor of her breast.20 Systemic treatment for the
patient included fluorouracil and prednisone, while chemotherapeutic treatment was a
combination of cyclophosphamide, adriamycin, amethopterin. The cells were resistant to both
systemic and chemotherapeutic treatment at the time and the patient died several months later.20
MDA-MD-231 cells have a mean chromosome number of 64, making them nearly triploid.21
They also have several identifying markers and they are capable of forming tumors in nude
mice.21
The MDA-MD-231 cell line has several characteristics that make it a good choice for the
wound closure and cell migration assay. First of all, this cell line grows fairly rapidly. This
helped to expedite the process of growing the cells from frozen samples, culturing the cells, and
subculturing the cells to create different passages. This also allows for efficient use of materials
and growth medium, as compared to cell lines that would take weeks to culture into a confluent
group and use up considerably more resources. A 1:10 dilution of MDA-MB-231 cells takes
approximately four to five days to reach confluence,21 which was optimal for this research.
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The growth properties of the MDA-MB-231 carcinoma cell line are essential for the cell
migration assay used in our research. Some cell lines used in cancer research do not have this
monolayer growth pattern and tend to grow in masses or clumps that do not adhere well to a
surface. However, MDA-MB-231 cells grow into a confluent monolayer on glass and treated
plates as shown in Figure 3. Formation of a
monolayer with uniform cell growth allows for
the wound to close evenly on all sides during
the wound closure assay to determine cell
migration. If the cells did not adhere well to
the plate, they could easily be dislodged
during the process of moving the plates from
the incubator, to the laminar flow cabinet, to

Fig 3. MDA-MB-231 cell growth properties.
This image depicts the confluent monolayer growth
that is typical of the MDA-MB-132 cell line

the microscope. This would of course

completely disrupt the uniform wound closure and cell migration.
The MDA-MB-231 cell line also falls under the category of “triple-negative” cancer
cells.22 Triple negative breast cancer cells are defined by their lack of estrogen receptors,
progesterone receptors, and human epidermal growth factor receptor 2 (HER2).23, 24 Only about
10-17% of breast carcinomas can be categorized as triple negative.24 Triple negative cancer cell
lines such as MDA-MB-231 are more aggressive and are not susceptible to some of the typical
systemic therapy options that target the estrogen receptor or HER2.24 Instead, chemotherapy
remains the only option for the treatment of triple negative cancers. This makes the study of
triple negative cell lines and their interactions with small molecules relevant from a medicinal,
pharmacological, and scientific standpoint.
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3B. Procedure for screening of small molecule libraries for antimigratory activity
The wound closure assay used to screen libraries of small molecules was developed by
the Fenteany lab,25 and the same procedures were essentially used in this screening.26 The small
molecule libraries were obtained from Chembridge and AnalytiCon. The screening was
conducted using BT-20, T47D, MDA-MB-231, MDA-MB-435, 4T1, and MDCK cells, which
were obtained from either the ATCC or the Yeung lab. The cells were shipped and stored frozen
at -80°C in cryovials. Cells were grown in a tissue culture incubator at 37°C with 5% CO2 in
minimum essential medium with additional Dulbecco’s modified Eagle medium containing 10%
fetal bovine serum (FBS). The medium was changed every two days. Cells were plated on 24well tissue culture-treated plates. When the cells reached confluence as depicted in Figure 4, the
medium was changed a final time and the experiment was started the next day.

A

B

Fig 4. MDA-MB-231 cell growth and proliferation. A.) The MDA-MB-231 cells are first plated
at a lower density in preparation for the wound closure/cell migration assay. B.) As the cells are fed,
they grow and proliferate until they become a confluent monolayer, ready for the assay.
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The carrier solvent for each compound was DMSO, used at less than 1%. Cells were
treated with 100 µM of each compound or 1% DMSO alone. The compounds to be screened or
the 1% DMSO control were mixed with fresh medium and added to the cells as a medium
change. The cells were exposed to the compounds or 1% DMSO for 30 minutes before the cell
monolayers were scratched with a micropipette tip, creating wounds of about 0.5–1.0 mm2 in
area as in Fig 5. After the 30 minute
incubation, the cells were observed
for wound closure every 12 hours for
the next 72 hours with an inverted
microscope. At each observation, the
wounds were deemed either open or
closed. Wounds that were still open
after the control 1% DMSO wounds
had closed indicated that the

Fig 5. Wounding for Cell Migration Screening Assay.
This image depicts size and shape of a typical wounded
monolayer of MDA-MB-231 cells at 0 hour of the cell
migration inhibition screening assay.

compounds had antimigratory
activity. However, it had to be verified that the inhibition of wound closure was not due to
cytotoxicity. As has often been quoted, “dead cells don’t move.” The trypan blue dye exclusion
assay was used to determine cytotoxicity.26
Several members of the cardiac glycoside group of natural products were among the
small molecules that displayed antimigratory activity in the screening of the two libraries. They
were deemed interesting choices for further investigation because, as explained in the
introduction, they have already been well studied as inhibitors of the protein Na,K-ATPase, but
not as inhibitors of cell migration. Analogs of digitoxin and ouabain were synthesized (see
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Chapter 2) and used for additional antimigratory wound closure assays to further analyze the
antimigratory activities of these cardiac glycosides.

3C. Procedure for conducting wound closure assay with a target molecule
For the assay of digitoxin and its analogues, the cell line used was the previously
described MDA-MB-231 human breast carcinoma cells. Each wound closure assay was done in
triplicate, with three different passages. In order to achieve these different passages, the cells had
to be subcultured. The cells were removed from the -80° freezer and thawed by rolling the
cryovial between one’s hands. The thawed cells in storage medium were then transferred to a
conical tube containing growth medium and centrifuged at 1000rpm for five minutes. The
supernatant was removed by aspiration and the remaining mass of cells was resuspended in
15mL of new growth medium. The cell suspension was then transferred and divided between
three tissue culture-treated plates and incubated at 37°C with 5% CO2. The cells were monitored
daily and the growth medium was changed every 24 to 48 hours.
When the MDA-MB-231 cells reached confluence on the tissue culture plates, they were
passaged, or “split.” The first step in splitting the cells was to remove the growth medium. This
was done by aspiration. A phosphate buffered saline (PBS) solution was used to wash or rinse
the plates three times in succession. This ensured the removal of any dead cells, cell wastes,
spent medium, or serum in the medium which inhibits trypsin. After washing the cells, they were
treated with trypsin, a protease that cleaves the bonds holding the cells to the surface of the
treated culture plate. After incubating the cells with trypsin for 15 minutes, the cells were no
longer attached to the plate so an equal volume of growth medium was added to quench the
trypsin reaction. These suspended cells were transferred to a conical tube and centrifuged at
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1000rpm for five minutes. The supernatant was removed and the cells were resuspended in
growth medium. The new solution of cells was then plated onto treated tissue culture plates at
different concentrations in order to create new passages that would take different amount of time
to reach confluence. After each of these new passages was split several times in the same
manner, they were split a final time. In this final split, they were diluted and plated in 96 well
plates, with 100μL in each well. These cells took about four days to reach confluence, during
which the medium was changed regularly. Once confluence was achieved in the final passage,
the cells were ready for the wound closure assay.
The glycoside analog to be tested was diluted with four-fold serial dilution, with
concentrations ranging from 1mM to 15nM. Once the glycoside solution was diluted in DMSO
and mixed with fresh medium, it was added to the cell culture. The MDA-MB-231 cells were
allowed to incubate with the glycoside solution for 30 minutes. After the incubation, the
monolayer of MDA-MB-231 cells was wounded using micropipette tip to produce a small oval
shape wound of about 0.5 to 1.0 mm2 in area. During this assay, an initial picture of the wound
was taken, and then taken again every three hours, for 24 hours, or as long as it took for the
control wounds to close entirely.

Fig 6. Comparison of wound closure in cells treated with glycoside and cells treated with DMSO control. The pictures of the
wounded cell monolayers were taken using an inverted microscope and camera attached to a computer. The top panel of pictures
represents one of the nine wells containing 1mM DMSO, and how the cells migrated to completely close the wound by 33 hours.
The bottom panel of pictures represents one of the nine wells containing
250μM digitoxin, where the percent closure of the initial
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wound is significantly less than that of the DMSO control. This indicates inhibition of cell migration by digitoxin.

Under ideal timing, the final set of pictures was taken just before the DMSO control wounds
were completely closed. This allowed for the most accurate measurement of percent closure of
the wounds treated with the glycoside compared to the DMSO control.
The cardiac glycosides were tested at each concentration in triplicate and using three
different passages of MDA-MB-231 cells. Each passage of cells was on its own 96 well plate.
This gave a total of nine trials for each concentration of the target glycoside analog. After the
assay was complete, the digital images were transferred to a PC to be processed. The NIH
software ImageJ (free download at http://rsb.info.nih.gov/ij/) was used to trace the perimeter of
the wound in each picture. The area enclosed by this tracing was computed in units of pixels.
Once the areas of the wounds had been measured at each time interval, it was possible to
calculate the percent closure by comparing the area of the wound at each time interval to the
initial area at hour 0. These values were compared to the percent closure of the wounds treated
with DMSO control. Minimum inhibitory values (MIC) and IC50 values were calculated with
GraphPad Prism software from concentration–response data.

3D. Relating results of antimigratory activities for digitoxin and analogs to structure
In the screening of the small molecule libraries, the cardiac glycosides ouabain, digitoxin,
and oleandrin all displayed antimigratory activity. So it was expected that the digitoxin analogs
synthesized would all have at least some antimigratory activity. The antimigratory activities are
expressed with two different values. The first is the minimum inhibitory concentration or MIC.
This is the lowest concentration of the cardiac glycoside that still displays antimigratory activity.
The second value is the half maximal inhibitory concentration, or the IC50. This is the
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concentration of cardiac glycoside that reduces cell migratory activity by half. Both the MIC and
the IC50 for digitoxin and its analogs are reported in Table 1.
Table 1. Measured activities for cell migration inhibition and Na+/K+-ATPase inhibition. These values were
determined by wound closure assays and Na+/K+-ATPase inhibition assays.

1

Percent Inhibition
(at highest concentration)
51.5% (250 μM)

MIC
(μM)
0.015

IC50
(μM)
0.046

Na+/K+ – ATPase
Inhibition Assay
IC50
(μM)
0.005

2

31.8% (250 μM)

0.24

0.260

0.097

3

36.8% (250 μM)

1.0

2.15

0.691

4a and 4b

43.2% (62.5 μM)

9.2

10.8

3.2

Cardiac Glycosides
Compound

Structure

Wound Closure Assay
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Digitoxin 1 proved to have greater antimigratory activity than any of the synthesized
analogs. 1 inhibited wound closure with MIC and IC50 values that were each on a nanomolar
scale at 15 nM and 46 nM respectively. Activity on a nanomolar scale is a characteristic common
to many of the most successful pharmaceutical drugs. It allows the drug to be used at low
dosages that do not come near its minimum lethal concentration (MLC). For digitoxin, the trypan
blue stain was performed at the conclusion of each wound closure assay to determine
cytotoxicity. However, it was a rather subjective test, which made it difficult to determine an
exact MLC value with any certainty. A large MLC and a small MIC is optimal for potential
drugs, which are rated using a therapeutic index (MLC/MIC). However, without an MLC for
digitoxin and its analogs, the calculation of therapeutic indices was not possible.
MIC and IC50 values provide information about the activity of a compound at lower
concentrations. The nanomolar MIC and IC50 values for 1 show that it has the strongest
antimigratory activity in terms of its ability to inhibit cell migration at low concentrations.
However, 1 also has the strongest antimigratory activity as a measurement of percent inhibition
at the highest concentrations. At 250 μM, 1 had 51.5% inhibition of cell migration, measured by
the wound closure assay. This is a significantly greater value than any of the digitoxin analogs
that were tested.
The only structural difference between 1 and 2 is the presence or absence of the three
sugars. So the antimigratory activities of 2 provide information on the importance of the sugar
moiety to the biological activity of cardiac glycosides. However, out of the digitoxin analogs
tested, 2 had the smallest drop in antimigratory activity, with MIC and IC50 values still at the
upper end of the nanomolar scale at 240 nM and 260 nM respectively. The percent inhibition at
a concentration of 250 μM also drops from 51.5% in 1 to 31.8% in 2.
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The wound closure assays conducted with 3 provide information about the butenolide
ring on cardiac glycosides and its role in the inhibition of cell migration. The reduction of the
C20-C22 double bond in the lactone ring of digitoxin is the only structural difference between
compounds 3 and 1, and it resulted in a decrease in antimigratory activity. The wound closure
assay for 2 resulted in the MIC and IC50 values for cell migration inhibition dropping out of the
nanomolar range and into the micromolar range at 1.0 μM and 2.15 μM. Although the reduction
of the C20-C22 double bond alters the structure of the butenolide ring and introduces a new
chirality center, it does not entirely compromise the conformational integrity of the lactone. It
would be very interesting to see if a complete opening of the butenolide ring would result in a
much more pronounced decrease in antimigratory activity. Unfortunately, the synthesis of this
type of analog has proved challenging and is still in progress as described in Chapter 2.
Compounds 4a and 4b had the lowest antimigratory activities among the digitoxin
analogs tested in the wound closure assay. The measured MIC value was 9.2 μM and the IC50
value was 10.8 μM. Two out of the three fundamental structures of cardiac glycosides described
in Chapter 1, have been compromised in 4a/4b. The sugars have been removed from C3 and the
curved shape of the steroid core has been altered by an elimination reaction. Direct comparison
of 4a/4b to 1 would leave uncertainty as to whether the differences in antimigratory activities are
as a result of the glycolysis or the elimination reaction that occurred in rings C and D. In order to
determine the loss of antimigratory activity as a direct result of the changes to the steroid core, it
is necessary to compare the MIC and IC50 values of 2 and 4a/4b. As shown in Table 1, the IC50
value increased from very significantly from 0.260 μM in 2 to 10.8 μM in 4a/4b. Although
4a/4b displayed the lowest antimigratory activity as expressed by MIC and IC50, they did have a
43.2% inhibition at the highest concentration (62.5 μM). This shows that at higher concentration,
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4a/4b have greater antimigratory activity than 2 and 3, which have percent inhibitions of 31.8%
and 36.8% respectively at a concentration of 250 μM. Again, biological activity at higher
concentrations is not as important pharmacologically because of concern about approaching the
MLC, but for our purposes it is worth noting.

3E. Correlation between antimigratory activities and Na+/K+ - ATPase inhibition for
digitoxin and analogs
After digitoxin and its analogs were tested for antimigratory activity with the wound
closure assay, Na+/K+ -ATPase inhibition assays were conducted to measure the capacity of
these molecules to inhibit the enzymatic activity of the Na+/K+ -ATPase protein. These assays
were conducted by Anniefer Magpusao of the Peczuh Group at the University of Connecticut.
Figure 7 provides an overview of the experimental procedure for the Na+/K+ -ATPase inhibition
assay performed by Magpusao.
The Na+/K+ -ATPase enzyme actively exchanges sodium and potassium across the
plasma membrane against their concentration gradients. In order to provide energy for the ion
exchange, the Na+/K+ -ATPase hydrolyzes ATP into APD and phosphate. In this Na+/K+ ATPase inhibition assay, the concentration of the newly generated phosphate is used as a direct
measurement of the activity of the Na+/K+ -ATPase pump. The phosphate is measured using
Taussky-Shorr reagent (1% w/v ammonium molybdate, 2.7% v/v sulfuric acid, and 5% w/v
ferrous sulfate hexahydrate).27, 28 The ammonium molybdate in Taussky-Shorr reagent reacts
with the inorganic phosphate to form PMO12O40 3-, which is in turn reduced by the ferrous sulfate
hexahydrate to form PMO12O40 7-, a blue colored ion that absorbs light at a wavelength of
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660nm.28 This absorbance is directly proportional to the concentration of phosphate in the
solution, which is in turn proportional to the enzymatic activity of Na+/K+ -ATPase pump.

Fig 7. Overview of Na+/K+ -ATPase inhibition assay.

Digitoxin or analog was added to a Na+/K+ -ATPase
solution in Tris Buffer (pH 7.8) and incubated with ATP
for 90 minutes. The reaction was quenched with TCA.
Tasusky-Shorr reagent was added to visualize the
concentration of inorganic phosphate. After 15 minutes,
the absorbance was read at 660 nm.
Treating the Na+/K+ -ATPase solution with digitoxin and analogs effectively inhibited
Na+/K+ -ATPase and resulted in decreased enzymatic activity. IC50 values were generated for
each of these compounds and they are included in Table 1.
Data from the wound closure assays and the Na+/K+ -ATPase inhibition assays were
compared to look for a correlation between the antimigratory activity and the Na+/K+ -ATPase
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inhibition activity of the cardiac glycosides digitoxin and its analogs. Figure 8 illustrates how
these data provide support for a positive correlation between these two activities.
12
10.8

IC 50 (μM)

10
8
Wound Closure Assay
6
Na+/K+ – ATPase
Inhibition Assay

4

3.2
2.15

2
0.046

0.005

0.260 0.097

0.691

0
1

2

3

4a / 4b

Cardiac Glycoside
Fig 8. Correlating antimigratory activity with Na+ / K+ - ATPase inhibitory activity in digitoxin
and its analogs. The cardiac glycoside analogs that had lower IC50 concentrations for inhibiting cell
migration also had lower IC50 concentrations for inhibiting the Na+/K+ - ATPase enzyme. As cell
migration inhibition decreased from analog to analog, Na+/K+ - ATPase inhibition also decreased.

Digitoxin 1, the most potent inhibitor of Na+/K+ -ATPase, was also the most potent inhibitor of
cell migration. 2 was second strongest inhibitor of both Na+/K+ -ATPase and cell migration. This
trend continued for 3 and 4a/4b, with the IC50 values increasing proportionally for each type of
activity. Additionally, none of the cardiac glycosides inhibited cell migration below the
concentration at which they inhibited the Na+/K+ -ATPase pump. The correlation was observed
by Magpusao when the same assays were done with the cardiac glycoside ouabain and its
analogs as part of current research that is not yet published.
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Chapter Four: Discussion
A. Summary of Results
The IC50 values of the wound closure data in Table 1 clearly show that digitoxin (1) is
the most potent inhibitor of cell migration. When the sugars were cleaved from digitoxin to give
digitoxigenin (2), there was a decrease in cell migration inhibition, but it still had an IC50 in the
nanomolar range. A much more significant decrease in cell migration inhibition came when the
the C20-C22 double bond in the butenolide ring was reduced in the analog 20,22dihydrodigitoxin (3). Then the most drastic decrease in cell migration inhibition was for the
elimination side product analog (4a/4b), where the structure of the steroid core was
compromised. This trend was exactly the same for the Na+/K+ -ATPase inhibition assay. Figure
8 presents this trend in a way that is easy to see. These results provide information as to which of
the three moieties of cardiac glycosides is most important for interaction with the Na+/K+ ATPase. The sugar is least important, flowed by the butenolide ring, and then the steroid core is
the moiety that is most crucial in the interaction between cardiac glycosides and the Na+/K+ ATPase protein.
The strong correlation between the IC50 values of the cell migration assay and the Na+/K+
-ATPase inhibition assay is another key result of this research. This correlation strongly suggest
that the cardiac glycoside digitoxin and its analogs are inhibiting cell migration through their
inhibition of the Na+/K+ -ATPase protein. This conclusion is further supported by the result that
no glycoside analog inhibited cell migration at a lower concentration than was necessary to
inhibit the Na+/K+ -ATPase pump.
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4B. Perspectives and Conclusions
Currently there are three main modes of action proposed for the observed effects f the
inhibition of the Na+/K+ -ATPase by cardiac glycosides. The classical Na+ lag hypothesis
explains the positive inotropic effect of cardiac glycosides on cardiac monocytes.29 In this
mechanism, inhibition of Na+/K+ -ATPase decreases the sodium ion concentration inside the
cells, which then leads to an increase in intracellular calcium concentration through the reverse
mode Na+/Ca2+ exchanger (NCX). This increase in calcium concentration eventually leads to
muscle contraction.29 The second mechanism of action proposes the existence of Na+/K+ ATPase signalosome.30 In this mechanism, it was proposed that certain populations of Na+/K+ ATPase exist in a caveolae along with a number of proteins such as Src,31 PLC,32 and P13K and
forms a signalosome. Binding of cardiac glycosides in the Na+/K+ -ATPase in this signalosome
activates these proteins and triggers various signal transduction cascades leading to the activation
of MAPK (ERK 1/2) pathway. Some of the signaling events were reported to occur even at
concentrations of cardiac glycosides that are too low to affect the ion homeostasis, thus
suggesting that the binding of cardiac glycosides to Na+/K+ -ATPase can initiate a signaling
cascade without affecting the pumping action of this ion transporter. The third method of action
was proposed in 2008, which calls into action the energy-sensing kinase AMPK.33 Since Na+/K+
-ATPase is responsible for the consumption of approximately 40% of the cellular ATP, its
inhibition greatly affects the total AMP/ATP ratio in the cell. This in turn is a signal for the
activation of AMPK. Soltoff and Hedden showed that inhibition of Na+/K+ -ATPase blocks the
phosphorylation of AMPK, which inturn leads to the activation of ERK 1/2.33
These different mechanism were observed using different experimental conditions and
different cell lines. In our study, we used triple negative MDA-MB-231 human breast cancer
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cells and looked into the correlation of IC50 values of different analogs of digitoxin with respect
to both cell migration and Na+/K+ -ATPase inhibition assays. We found that the IC50 values for
digitoxin and its analogs for the cell migration assay correlate very well with the IC50 values for
the Na+/K+ -ATPase inhibition assay. Also, we did not observe inhibition of cell migration below
the concentration of cardiac glycoside that inhibits Na+/K+ -ATPase. Based on these results, it is
more likely that the mechanism of the inhibition of cell migration and its analogs involves the
perturbation of the Na+, K+, and Ca2+ ion homeostasis caused by the inhibition of Na+/K+ ATPase. The next interesting step then to explore for project would be to evaluate how digitoxin,
its analogs, and other cardiac glycosides and other Na+/K+ -ATPase inhibitors affect the
concentration of these three key ions. Correlating this with the observed inhibition of cell
migration might provide further information on how cardiac glycosides inhibit cell migration.
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13C NMR of Digitoxin 1

Appendix:
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13C NMR of Digitoxigenin 2
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13C NMR of
Elimination Side Product 4a/4b

40

13C NMR of
20,22-dihydrodigitoxigenin 5
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